Cardiac safety of trastuzumab without an anthracycline in patients with HER2-positive early stage breast cancer: A single center experience

被引：0
|
作者：
Mukku, R. B. [1 ]
Verma, S. [1 ]
Liu, J. [1 ]
Steingart, R. [1 ]
Hudis, C. [1 ]
Yu, A. F. [1 ]
Dang, C. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P4-14-09
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Cardiac safety of trastuzumab without an anthracycline in patients with HER2-positive early stage breast cancer: A single center experience
    Mukku, R. B.
    Verma, S.
    Liu, J.
    Steingart, R.
    Hudis, C.
    Yu, A. F.
    Dang, C.
    CANCER RESEARCH, 2016, 76
  • [2] Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer
    Anthony F. Yu
    Roy B. Mukku
    Shivani Verma
    Jennifer E. Liu
    Kevin C. Oeffinger
    Richard M. Steingart
    Clifford A. Hudis
    Chau T. Dang
    Breast Cancer Research and Treatment, 2017, 166 : 241 - 247
  • [3] Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer
    Yu, Anthony F.
    Mukku, Roy B.
    Verma, Shivani
    Liu, Jennifer E.
    Oeffinger, Kevin C.
    Steingart, Richard M.
    Hudis, Clifford A.
    Dang, Chau T.
    BREAST CANCER RESEARCH AND TREATMENT, 2017, 166 (01) : 241 - 247
  • [4] Should trastuzumab be administered concomitantly with anthracycline in women with early, HER2-positive breast cancer?
    Montemurro, Filippo
    TRANSLATIONAL CANCER RESEARCH, 2014, 3 (06) : 541 - 546
  • [5] Nine-weeks of adjuvant trastuzumab in HER2-positive breast cancer: A single center experience
    Kizilarslanoglu, Cemal
    Petekkaya, Ibrahim
    Babacan, Taner
    Altundag, Kadri
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [6] Cardiac safety guidelines for the adjuvant use of trastuzumab (Herceptin®) in HER2-positive early breast cancer
    Ewer, M. S.
    Perez, E. A.
    Baselga, J.
    Bell, R.
    Brutsaert, D.
    Marty, M.
    Pienkowski, T.
    Suter, T. M.
    BREAST, 2007, 16 : S63 - S63
  • [7] Long term outcome of HER2-positive early breast cancer patients in the trastuzumab era: a single centre experience
    Aravind, P.
    Jingree, C.
    Castell, F.
    Rigg, A.
    BREAST, 2017, 32 : S22 - S22
  • [8] Neoadjuvant trastuzumab therapy with or without anthracycline containing chemotherapy for HER2-positive primary breast cancer
    Horiguchi, J.
    Koibuchi, Y.
    Rokutanda, N.
    Nagaoka, R.
    Sato, A.
    Odawara, H.
    Tokiniwa, H.
    Kikuchi, M.
    Lino, Y.
    Takeyoshi, I.
    EJC SUPPLEMENTS, 2010, 8 (03): : 73 - 73
  • [9] Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience
    Singh, Jasmeet C.
    Mamtani, Anita
    Barrio, Andrea
    Morrow, Monica
    Sugarman, Steven
    Jones, Lee W.
    Yu, Anthony F.
    Argolo, Daniel
    Smyth, Lilian M.
    Modi, Shanu
    Schweber, Sarah
    Boafo, Camilla
    Patil, Sujata
    Norton, Larry
    Baselga, Jose
    Hudis, Clifford A.
    Dang, Chau
    ONCOLOGIST, 2017, 22 (02): : 139 - 143
  • [10] Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer
    Yu, Anthony F.
    Manrique, Carlos
    Pun, Shawn
    Liu, Jennifer E.
    Mara, Elton
    Fleisher, Amartin
    Patil, Sujata
    Jones, Lee W.
    Steingart, Richard M.
    Hudis, Clifford A.
    Dang, Chau T.
    ONCOLOGIST, 2016, 21 (04): : 418 - 424
12345